advertisement
Clark KL 14
Showing records 1 to 14 |
Display all abstracts from Clark KL80215 The affinity, intrinsic activity and selectivity of a structurally novel EP receptor agonist at human prostanoid receptorsColeman RA; Coleman RA
British Journal of Pharmacology 2019; 176: 687-698
80927 A Highly Effective and Ultra-Long-Acting Anti-Glaucoma Drug, with a Novel Periorbital Delivery MethodWoodward DF; Wang JW
Journal of Ocular Pharmacology and Therapeutics 2019; 35: 265-277
80215 The affinity, intrinsic activity and selectivity of a structurally novel EP receptor agonist at human prostanoid receptorsWoodrooffe AJ; Woodrooffe AJ
British Journal of Pharmacology 2019; 176: 687-698
80927 A Highly Effective and Ultra-Long-Acting Anti-Glaucoma Drug, with a Novel Periorbital Delivery MethodColeman RA
Journal of Ocular Pharmacology and Therapeutics 2019; 35: 265-277
80215 The affinity, intrinsic activity and selectivity of a structurally novel EP receptor agonist at human prostanoid receptorsClark KL
British Journal of Pharmacology 2019; 176: 687-698
80927 A Highly Effective and Ultra-Long-Acting Anti-Glaucoma Drug, with a Novel Periorbital Delivery MethodColeman RA
Journal of Ocular Pharmacology and Therapeutics 2019; 35: 265-277
80215 The affinity, intrinsic activity and selectivity of a structurally novel EP receptor agonist at human prostanoid receptorsClark KL
British Journal of Pharmacology 2019; 176: 687-698
80927 A Highly Effective and Ultra-Long-Acting Anti-Glaucoma Drug, with a Novel Periorbital Delivery MethodWoodrooffe AJ
Journal of Ocular Pharmacology and Therapeutics 2019; 35: 265-277
80215 The affinity, intrinsic activity and selectivity of a structurally novel EP receptor agonist at human prostanoid receptorsToris CB
British Journal of Pharmacology 2019; 176: 687-698
80927 A Highly Effective and Ultra-Long-Acting Anti-Glaucoma Drug, with a Novel Periorbital Delivery MethodWoodrooffe AJ; Clark KL; Clark KL
Journal of Ocular Pharmacology and Therapeutics 2019; 35: 265-277
80215 The affinity, intrinsic activity and selectivity of a structurally novel EP receptor agonist at human prostanoid receptorsFan S; Wang JW
British Journal of Pharmacology 2019; 176: 687-698
80927 A Highly Effective and Ultra-Long-Acting Anti-Glaucoma Drug, with a Novel Periorbital Delivery MethodStamer WD
Journal of Ocular Pharmacology and Therapeutics 2019; 35: 265-277
80215 The affinity, intrinsic activity and selectivity of a structurally novel EP receptor agonist at human prostanoid receptorsWoodward DF
British Journal of Pharmacology 2019; 176: 687-698
80927 A Highly Effective and Ultra-Long-Acting Anti-Glaucoma Drug, with a Novel Periorbital Delivery MethodTao G; Fan S; Toris CB
Journal of Ocular Pharmacology and Therapeutics 2019; 35: 265-277
Issue 20-3
Change Issue
advertisement